Research and Development Expenses Breakdown: AstraZeneca PLC vs Alpine Immune Sciences, Inc.

AstraZeneca vs. Alpine: R&D Investment Strategies Unveiled

__timestampAlpine Immune Sciences, Inc.AstraZeneca PLC
Wednesday, January 1, 2014121995475579000000
Thursday, January 1, 2015160540005997000000
Friday, January 1, 2016233160005890000000
Sunday, January 1, 2017106260005757000000
Monday, January 1, 2018289700005932000000
Tuesday, January 1, 2019358470005958000000
Wednesday, January 1, 2020271850005991000000
Friday, January 1, 2021587420009736000000
Saturday, January 1, 2022702430009762000000
Sunday, January 1, 20238090400010935000000
Monday, January 1, 202413583000000
Loading chart...

Data in motion

A Tale of Two Innovators: AstraZeneca vs. Alpine Immune Sciences

In the dynamic world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, AstraZeneca PLC and Alpine Immune Sciences, Inc. have showcased contrasting R&D investment strategies. AstraZeneca, a global giant, consistently allocated substantial resources, with R&D expenses peaking at approximately $10.9 billion in 2023, marking a 96% increase from 2014. This commitment underscores AstraZeneca's relentless pursuit of groundbreaking therapies.

Conversely, Alpine Immune Sciences, a nimble biotech firm, demonstrated a more modest yet steadily increasing R&D investment, growing by over 560% from 2014 to 2023. This growth trajectory highlights Alpine's strategic focus on innovation within its niche. The juxtaposition of these two companies offers a fascinating glimpse into how different scales of operation approach the challenge of innovation in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025